Check · Diet · Fasting-mimicking diet In review

Does ProLon's fasting-mimicking diet trigger cellular rejuvenation and reduce biological age?

Claim attributed to Valter Longo (USC), who developed the FMD and founded L-Nutra/ProLon; L-Nutra markets the product. , Longo is senior author on the pivotal human trials and founded L-Nutra, which sells the FMD as ProLon. He held majority equity but pledged to donate his consulting fees and 100% of his equity to the nonprofit Create Cures Foundation; USC also holds a financial interest.

Verdict Mixed

Evidence grade C Low certainty

Periodic FMD cycles produce real but modest short-term cardiometabolic improvements, especially in higher-risk people. The leap to "cellular rejuvenation" and a lower "biological age" rests on a surrogate blood-marker clock and mouse data, not on demonstrated rejuvenation or any hard human outcome.

It moves blood markers for a few weeks and was tested with the inventor's own product; it has never been shown to make a human live longer or healthier.

The theory

What it’s supposed to target

IGF-1 + mTOR (lowered)
Autophagy + stem-cell renewal
Ketosis
Cardiometabolic markers

The fasting-mimicking diet tries to capture the benefits of a multi-day fast while still letting you eat. By keeping calories, and especially protein and sugar, very low for about five days, it aims to drop IGF-1 and mTOR growth signaling and tip the body into ketosis, conditions thought to trigger autophagy (cellular self-cleaning) and, on refeeding, a wave of stem-cell renewal. The theory, built largely in Valter Longo's lab, is that periodic cycles prompt the body to clear damaged cells and rebuild younger ones.

The human data are real but narrower than the marketing. Controlled trials show FMD cycles improve weight, blood pressure, blood sugar, IGF-1, and inflammation, with the biggest gains in people who began with elevated risk, and a recent paper reported a drop on a biological-age clock. The caveats: a biological-age clock is a surrogate, not proof of a longer life; much of the benefit may simply reflect calorie restriction and weight loss; and the diet's creator founded the company that sells it (he says he donates his profits, worth noting on both counts). Genuine short-term cardiometabolic value, an unproven rejuvenation claim.

Mechanism is theory, not proof. A plausible pathway explains why something might work, not whether it does. The verdict rests on the evidence below, not the elegance of the theory.

The claim

What would have to be true

FMD must change blood markers short-term: holds, well-supported in two small trials.

Those changes must exceed plain calorie restriction/weight loss: unproven, no active-CR comparator trial exists.

A lower surrogate clock must equal reversed biological aging: unproven, the index is not validated for this over weeks.

This must translate into longer, healthier human life: untested, no hard-outcome data.

The evidence

What the evidence actually shows

What the human trials actually show

The flagship RCT (Wei et al. 2017, 100 randomized, 71 completers) found that 3 monthly 5-day FMD cycles significantly cut body weight (~-2.6 kg), trunk and total fat, systolic BP (~-4.5 mmHg) and IGF-1 (~-22 ng/ml) versus controls. Crucially, fasting glucose, triglycerides, cholesterol and CRP were not significantly different in that primary comparison; those reductions appeared only in a pooled/post hoc analysis. Benefits concentrated in people who started with elevated risk markers. This is genuine short-term cardiometabolic benefit, not demonstrated rejuvenation.

Where 'biological age' comes from

The 2024 '2.5 years younger' result (Brandhorst et al., Nat Commun) is a secondary/exploratory analysis pooling the 100-person trial with a 44-person cardiometabolic-risk trial. The 'biological age' is a Levine-type composite of 7 routine blood markers plus blood pressure, explicitly not an epigenetic clock and not a hard outcome. The authors report the change was statistically independent of weight loss (BMI association p=0.35), their main argument it is more than dieting. But no trial used an active calorie-restriction comparator, so an FMD-specific effect cannot be cleanly separated, and independent scientists quoted by STAT argued weight loss likely explains much of the benefit.

Evidence quality

Studies, graded, and who paid

FMD cycles reduce weight, body fat, blood pressure and IGF-1 short-term B Moderate certainty

Significant in the primary RCT comparison; largest in at-risk participants.

FMD lowers a Levine-type 'biological age' index by ~2.5 years C Low certainty

True for a 7-marker clinical-chemistry surrogate, from a secondary/exploratory analysis; not an epigenetic clock or hard outcome.

FMD triggers cellular rejuvenation and extends human healthspan D Very low certainty

Best supported in mice; no human rejuvenation or long-term outcome data exist.

Cited studies with type, size, funding/conflicts, and limitations.
#	Study	Type	Size	Funding / COI	Key limitations
100	Wei et al. 2017, Sci Transl Med (pivotal RCT)	Randomized controlled crossover trial	100 randomized; 71 completed 3 cycles	Industry-funded USC chair fund (Longo); FMD supplied by L-Nutra; Longo and a co-author held equity and recused from data collection/analysis; equity pledged to Create Cures.	Modest size, short term; key glucose/lipid/CRP cuts only in pooled/post hoc, not primary comparison.
144	Brandhorst et al. 2024, Nat Commun ('biological age')	Secondary/exploratory analysis of two trials	Pooled 100 + 44 participants	Industry-funded Longo (senior author) founded L-Nutra; FMD is L-Nutra's ProLon; formulations belong to USC and L-Nutra. Full COI paragraph not extracted from page.	Surrogate blood-marker clock, not epigenetic; secondary endpoint; no active-CR comparator; no hard outcomes.
3	USC press release 2024	University press release	n/a	Industry-funded Issued by Longo's institution; USC discloses a financial interest in L-Nutra.	Source of 'rejuvenation' and 'biologically younger' framing; not independent evidence.
4	Robbins, STAT News 2017	Independent investigative journalism	n/a	Independent No industry funding of the reporting.	Documents the commercial conflict; quotes independent scientists noting weight loss may explain benefits and head-to-head human comparisons are lacking.

The same conflicted group produced the favorable trials, the 'biological age' analysis, and the strongest marketing language; effects largely overlap with what plain weight loss achieves.

See who funded the studies behind every Caveat check

Stay neutral

Unproven ≠ disproven

'Rejuvenation' and 'reverses aging' are best supported in mice. In humans the data show short-term cardiometabolic improvement plus a surrogate-clock change, which is unproven as reversed aging, not disproven.

The gap

Where claim and evidence diverge

No trial isolates the FMD from generic calorie restriction with an active comparator, and there are no long-term human outcomes (cardiovascular events, cancer, mortality) or data on durability between cycles.

Follow the funding

The money trail

Longo founded L-Nutra, which sells the FMD as ProLon (~$150-300 per 5-day cycle), and is senior author on the pivotal trials; L-Nutra supplied the product used in them.

He retained majority ownership but pledged in 2017 to stop taking consulting fees and donate 100% of his equity to the nonprofit Create Cures Foundation; USC also holds a disclosed financial interest.

Bottom line

The honest read

The FMD is a plausible, real short-term cardiometabolic tool, strongest for higher-risk people. The 'rejuvenation' and 'younger biological age' framing outruns the human evidence and traces back to the inventor's own company.

Falsifiable

What would change this verdict

A large, independent (non-Longo, non-L-Nutra) RCT with an active calorie-restriction comparator showing FMD-specific benefit beyond weight loss.

Long-term human outcome data (validated aging clocks or hard endpoints like disease/mortality) showing durable benefit from repeated cycles.

Receipts

Sources

Common questions